The role of proactive therapeutic drug monitoring in guiding infliximab therapeutic optimization in pediatric patients with Crohn's disease: A retrospective study
Abstract Therapeutic drug monitoring (TDM) plays an important role in guiding treatment plan adjustments and clinical outcomes in Crohn's disease. To evaluate the role of TDM‐guided optimization of infliximab dosage in patients with pediatric Crohn's disease. Medical records of patients wi...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-12-01
|
| Series: | Pediatric Discovery |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/pdi3.96 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850121147202404352 |
|---|---|
| author | Junya Song Huihui Zhang Huihua Zhang Ximing Xu Xiaohua Liang Yongfang Liu Xiaomei Song Hong Guo Xue Zhan Jinlin Song Xiaoqin Zhou |
| author_facet | Junya Song Huihui Zhang Huihua Zhang Ximing Xu Xiaohua Liang Yongfang Liu Xiaomei Song Hong Guo Xue Zhan Jinlin Song Xiaoqin Zhou |
| author_sort | Junya Song |
| collection | DOAJ |
| description | Abstract Therapeutic drug monitoring (TDM) plays an important role in guiding treatment plan adjustments and clinical outcomes in Crohn's disease. To evaluate the role of TDM‐guided optimization of infliximab dosage in patients with pediatric Crohn's disease. Medical records of patients with pediatric Crohn's disease who were treated with infliximab and had proactive TDM from June 2020 to June 2022 at the Children's Hospital of Chongqing Medical University were included. Baseline influencing factors for infliximab trough concentration (TC) and clinical outcomes before and after the treatment change were analyzed to assess the value of adjusting treatment in the patients. Forty‐six patients (male‐to‐female ratio = 1.55:1, age <18 years) were included. Univariate and multivariate analyses showed that hormone exposure (odds ratio: 0.042, 95% confidence interval: 0.002–0.924, p = 0.044), perianal lesions (5.813, 0.984–34.349, p = 0.052), simplified endoscopic score for Crohn's disease (1.656, 1.065–2.577, p = 0.025), and total protein (TP) (0.851, 0.749–0.967, p = 0.014) were correlated with infliximab TC. Shortening the treatment interval increased the infliximab TC (pre vs. post = 1.69 ± 0.8 vs. 12.03 ± 6.64, p = 0.001, n = 12) after 93.9 ± 37.47 days, decreased the pediatric Crohn's disease activity index and simplified endoscopic score for Crohn's disease, and increased the biochemical remission, clinical remission, endoscopic remission, and endoscopic response rates; however, there was no statistical significance. Hormone exposure, perianal lesions, simplified endoscopic score for Crohn's disease, and TP levels before the first infliximab use affected the infliximab TC. Shortening the treatment interval can improve infliximab TC levels and clinical outcomes. |
| format | Article |
| id | doaj-art-eac455d2e25a43ce87fbedd27cf6ba54 |
| institution | OA Journals |
| issn | 2835-558X 2835-5598 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | Pediatric Discovery |
| spelling | doaj-art-eac455d2e25a43ce87fbedd27cf6ba542025-08-20T02:35:11ZengWileyPediatric Discovery2835-558X2835-55982024-12-0124n/an/a10.1002/pdi3.96The role of proactive therapeutic drug monitoring in guiding infliximab therapeutic optimization in pediatric patients with Crohn's disease: A retrospective studyJunya Song0Huihui Zhang1Huihua Zhang2Ximing Xu3Xiaohua Liang4Yongfang Liu5Xiaomei Song6Hong Guo7Xue Zhan8Jinlin Song9Xiaoqin Zhou10Department of Gastroenterology Children's Hospital of Chongqing Medical University (CHCQMU) Chongqing ChinaDepartment of Gastroenterology Children's Hospital of Chongqing Medical University (CHCQMU) Chongqing ChinaDepartment of Gastroenterology Children's Hospital of Chongqing Medical University (CHCQMU) Chongqing ChinaNational Clinical Research Center for Child Health and Disorders Ministry of Education Key Laboratory of Child Development and Disorders Chongqing Key Laboratory of Pediatrics Chongqing Key Laboratory of Child Health and Nutrition Chongqing ChinaNational Clinical Research Center for Child Health and Disorders Ministry of Education Key Laboratory of Child Development and Disorders Chongqing Key Laboratory of Pediatrics Chongqing Key Laboratory of Child Health and Nutrition Chongqing ChinaNational Clinical Research Center for Child Health and Disorders Ministry of Education Key Laboratory of Child Development and Disorders Chongqing Key Laboratory of Pediatrics Chongqing Key Laboratory of Child Health and Nutrition Chongqing ChinaDepartment of Gastroenterology Chongqing General Hospital Chongqing ChinaDepartment of Gastroenterology Chongqing General Hospital Chongqing ChinaDepartment of Gastroenterology Children's Hospital of Chongqing Medical University (CHCQMU) Chongqing ChinaCollege of Stomatology Chongqing Key Laboratory for Oral Diseases and Biomedical Sciences Chongqing Municipal Key Laboratory of Oral Biomedical Engineering of Higher Education Chongqing ChinaDepartment of Gastroenterology Children's Hospital of Chongqing Medical University (CHCQMU) Chongqing ChinaAbstract Therapeutic drug monitoring (TDM) plays an important role in guiding treatment plan adjustments and clinical outcomes in Crohn's disease. To evaluate the role of TDM‐guided optimization of infliximab dosage in patients with pediatric Crohn's disease. Medical records of patients with pediatric Crohn's disease who were treated with infliximab and had proactive TDM from June 2020 to June 2022 at the Children's Hospital of Chongqing Medical University were included. Baseline influencing factors for infliximab trough concentration (TC) and clinical outcomes before and after the treatment change were analyzed to assess the value of adjusting treatment in the patients. Forty‐six patients (male‐to‐female ratio = 1.55:1, age <18 years) were included. Univariate and multivariate analyses showed that hormone exposure (odds ratio: 0.042, 95% confidence interval: 0.002–0.924, p = 0.044), perianal lesions (5.813, 0.984–34.349, p = 0.052), simplified endoscopic score for Crohn's disease (1.656, 1.065–2.577, p = 0.025), and total protein (TP) (0.851, 0.749–0.967, p = 0.014) were correlated with infliximab TC. Shortening the treatment interval increased the infliximab TC (pre vs. post = 1.69 ± 0.8 vs. 12.03 ± 6.64, p = 0.001, n = 12) after 93.9 ± 37.47 days, decreased the pediatric Crohn's disease activity index and simplified endoscopic score for Crohn's disease, and increased the biochemical remission, clinical remission, endoscopic remission, and endoscopic response rates; however, there was no statistical significance. Hormone exposure, perianal lesions, simplified endoscopic score for Crohn's disease, and TP levels before the first infliximab use affected the infliximab TC. Shortening the treatment interval can improve infliximab TC levels and clinical outcomes.https://doi.org/10.1002/pdi3.96Crohn's diseaseinfliximabpediatrictherapeutic drug monitoring |
| spellingShingle | Junya Song Huihui Zhang Huihua Zhang Ximing Xu Xiaohua Liang Yongfang Liu Xiaomei Song Hong Guo Xue Zhan Jinlin Song Xiaoqin Zhou The role of proactive therapeutic drug monitoring in guiding infliximab therapeutic optimization in pediatric patients with Crohn's disease: A retrospective study Pediatric Discovery Crohn's disease infliximab pediatric therapeutic drug monitoring |
| title | The role of proactive therapeutic drug monitoring in guiding infliximab therapeutic optimization in pediatric patients with Crohn's disease: A retrospective study |
| title_full | The role of proactive therapeutic drug monitoring in guiding infliximab therapeutic optimization in pediatric patients with Crohn's disease: A retrospective study |
| title_fullStr | The role of proactive therapeutic drug monitoring in guiding infliximab therapeutic optimization in pediatric patients with Crohn's disease: A retrospective study |
| title_full_unstemmed | The role of proactive therapeutic drug monitoring in guiding infliximab therapeutic optimization in pediatric patients with Crohn's disease: A retrospective study |
| title_short | The role of proactive therapeutic drug monitoring in guiding infliximab therapeutic optimization in pediatric patients with Crohn's disease: A retrospective study |
| title_sort | role of proactive therapeutic drug monitoring in guiding infliximab therapeutic optimization in pediatric patients with crohn s disease a retrospective study |
| topic | Crohn's disease infliximab pediatric therapeutic drug monitoring |
| url | https://doi.org/10.1002/pdi3.96 |
| work_keys_str_mv | AT junyasong theroleofproactivetherapeuticdrugmonitoringinguidinginfliximabtherapeuticoptimizationinpediatricpatientswithcrohnsdiseasearetrospectivestudy AT huihuizhang theroleofproactivetherapeuticdrugmonitoringinguidinginfliximabtherapeuticoptimizationinpediatricpatientswithcrohnsdiseasearetrospectivestudy AT huihuazhang theroleofproactivetherapeuticdrugmonitoringinguidinginfliximabtherapeuticoptimizationinpediatricpatientswithcrohnsdiseasearetrospectivestudy AT ximingxu theroleofproactivetherapeuticdrugmonitoringinguidinginfliximabtherapeuticoptimizationinpediatricpatientswithcrohnsdiseasearetrospectivestudy AT xiaohualiang theroleofproactivetherapeuticdrugmonitoringinguidinginfliximabtherapeuticoptimizationinpediatricpatientswithcrohnsdiseasearetrospectivestudy AT yongfangliu theroleofproactivetherapeuticdrugmonitoringinguidinginfliximabtherapeuticoptimizationinpediatricpatientswithcrohnsdiseasearetrospectivestudy AT xiaomeisong theroleofproactivetherapeuticdrugmonitoringinguidinginfliximabtherapeuticoptimizationinpediatricpatientswithcrohnsdiseasearetrospectivestudy AT hongguo theroleofproactivetherapeuticdrugmonitoringinguidinginfliximabtherapeuticoptimizationinpediatricpatientswithcrohnsdiseasearetrospectivestudy AT xuezhan theroleofproactivetherapeuticdrugmonitoringinguidinginfliximabtherapeuticoptimizationinpediatricpatientswithcrohnsdiseasearetrospectivestudy AT jinlinsong theroleofproactivetherapeuticdrugmonitoringinguidinginfliximabtherapeuticoptimizationinpediatricpatientswithcrohnsdiseasearetrospectivestudy AT xiaoqinzhou theroleofproactivetherapeuticdrugmonitoringinguidinginfliximabtherapeuticoptimizationinpediatricpatientswithcrohnsdiseasearetrospectivestudy AT junyasong roleofproactivetherapeuticdrugmonitoringinguidinginfliximabtherapeuticoptimizationinpediatricpatientswithcrohnsdiseasearetrospectivestudy AT huihuizhang roleofproactivetherapeuticdrugmonitoringinguidinginfliximabtherapeuticoptimizationinpediatricpatientswithcrohnsdiseasearetrospectivestudy AT huihuazhang roleofproactivetherapeuticdrugmonitoringinguidinginfliximabtherapeuticoptimizationinpediatricpatientswithcrohnsdiseasearetrospectivestudy AT ximingxu roleofproactivetherapeuticdrugmonitoringinguidinginfliximabtherapeuticoptimizationinpediatricpatientswithcrohnsdiseasearetrospectivestudy AT xiaohualiang roleofproactivetherapeuticdrugmonitoringinguidinginfliximabtherapeuticoptimizationinpediatricpatientswithcrohnsdiseasearetrospectivestudy AT yongfangliu roleofproactivetherapeuticdrugmonitoringinguidinginfliximabtherapeuticoptimizationinpediatricpatientswithcrohnsdiseasearetrospectivestudy AT xiaomeisong roleofproactivetherapeuticdrugmonitoringinguidinginfliximabtherapeuticoptimizationinpediatricpatientswithcrohnsdiseasearetrospectivestudy AT hongguo roleofproactivetherapeuticdrugmonitoringinguidinginfliximabtherapeuticoptimizationinpediatricpatientswithcrohnsdiseasearetrospectivestudy AT xuezhan roleofproactivetherapeuticdrugmonitoringinguidinginfliximabtherapeuticoptimizationinpediatricpatientswithcrohnsdiseasearetrospectivestudy AT jinlinsong roleofproactivetherapeuticdrugmonitoringinguidinginfliximabtherapeuticoptimizationinpediatricpatientswithcrohnsdiseasearetrospectivestudy AT xiaoqinzhou roleofproactivetherapeuticdrugmonitoringinguidinginfliximabtherapeuticoptimizationinpediatricpatientswithcrohnsdiseasearetrospectivestudy |